A Phase I/II Study of CPI-613 in Combination With Induction/Consolidation in Older AML Patients
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs CPI 613 (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 31 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2016.
- 26 Jul 2016 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped was Drug Supply Issues.
- 22 Oct 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017 as reported by ClinicalTrials.gov.